Research programme: small molecule therapeutics - Action Pharma

Drug Profile

Research programme: small molecule therapeutics - Action Pharma

Alternative Names: AP 1102; AP 1130; AP 1170; AP 1189; AP 405; AP11-series

Latest Information Update: 10 Jun 2010

Price : $50

At a glance

  • Originator Action Pharma
  • Class Small molecules
  • Mechanism of Action Melanocortin receptor agonists; Melanocortin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Atopic dermatitis; Inflammation; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 10 Jun 2010 Preclinical trials in Type-2 diabetes mellitus in Denmark (PO)
  • 23 Sep 2008 Preclinical development is ongoing in Denmark
  • 16 Mar 2006 Preclinical trials in Inflammation in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top